SCHEMBL4928663

SCHEMBL4928663

COc1cc(OC)c(-c2noc3ccccc23)cc1CNc1ccc(C)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
GAA P10253 7/20 0.44
LMNA P02545 5/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 4/20 0.44
NPC1 O15118 3/20 0.44
TSHR P16473 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPK1 P28482 2/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
GFER P55789 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RAB9A P51151 2/20 0.40
DHFR P00374 1/20 0.40
GLA P06280 1/20 0.39
CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4932865 0.93 MAPT (0.50) MAPTGAALMNAMEN1KMT2A
SCHEMBL4933048 0.89 HIF1A (0.41) MAPTGAALMNAMEN1KMT2A
SCHEMBL4934925 0.88 MAPT (0.41) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL4928618 0.84 MAPT (0.54) MAPTGAAALDH1A1NPC1TDP1
SCHEMBL4935041 0.81 MAPT (0.51) MAPTGAALMNAKMT2AALDH1A1
SCHEMBL4931003 0.79 ESR1 (0.44) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL4931993 0.75 ESR1 (0.41) MAPTLMNANPC1KDM4EMAPK1
SCHEMBL4933058 0.73 ESR1 (0.39) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL2767665 0.73 EPHX2 (0.48) MAPTGAALMNAMEN1KMT2A
SCHEMBL4928671 0.73 ESR1 (0.37) MAPTALDH1A1L3MBTL1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer UGT2B7, UGT2B17, CYP4X1 MAPT 4708/4885GAA 331/4885LMNA 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.